cases consist of renal cell carcinomas (RCCs), which are genetically and histologically distinct from cancers of the renal pelvis. An increased understanding of RCC biology coupled with new clinical trials data have resulted in the availability of
Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas
Elizabeth R. Plimack and Gary R. Hudes
metastatic clear cell RCC Describe second-line management of patients with metastatic clear cell RCC I n the past 5 years, 6 new agents were approved for the treatment of renal cell carcinoma (RCC). These can be broadly categorized into 2 groups: vascular
Eric Jonasch and Robert J. Motzer
In the past 10 years, much has changed in the management of advanced renal cell carcinoma (RCC; Figure 1 ). The treatment of early-stage disease has become less morbid, with the widespread adoption of robotic surgical techniques and the increased
Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli and Pierre I. Karakiewicz
-up have a higher probability of remaining disease-free. 1 However, the magnitude of improved survival is difficult to estimate. Two studies 2 , 3 address cancer-specific CS in patients with nonmetastatic renal cell carcinoma (nmRCC): one is a population
Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo and Cristina Rodríguez-Antona
Chromophobe renal cell carcinoma (chRCC) is the third most frequent kidney cancer histologic subtype, accounting for approximately 5% of all RCC cases. At diagnosis, chRCC is generally confined to the kidney but can metastasize. At advanced stages
Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas and Cristina Rodríguez-Antona
Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and
Philip J. Saylor and M. Dror Michaelson
Petrylak D Thompson S . Cytotoxic chemotherapy for advanced renal cell carcinoma . Urol Clin North Am 1993 ; 20 : 303 – 321 . 3 Atkins MB Regan M McDermott D . Update on the role of interleukin 2 and other cytokines in the treatment of
Mark D. Tyson and Sam S. Chang
The incidence of renal cell carcinoma (RCC) has been steadily increasing for decades. 1 The mainstay of treatment for clinically localized disease is radical nephrectomy and, when technically feasible, partial nephrectomy. Yet, up to 20% to 30
Neil K. Taunk, Daniel E. Spratt, Mark Bilsky and Yoshiya Yamada
Identify those patients with metastatic RCC who may benefit the most from SRS treatment Renal Cell Carcinoma and the Case for Local Therapy for Metastatic Disease Renal cell carcinoma (RCC) is the seventh most common malignancy in the United
Matthew Zibelman and Elizabeth R. Plimack
. Combination Phase III Trials Using Immune Checkpoint Blockade in First-Line Metastatic Renal Cell Carcinoma referred after surgery by urologists to medical oncologists, removing the potential impact of systemic therapy on surgical timing and outcome